Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MenACYW conjugate vaccine versus licensed quadrivalent meningococcal vaccines in healthy participants in India and South Africa
2020-004341-36Phase 3
- Sponsor
- Sanofi
- Start
- Dec 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (4 arms), sponsored by Sanofi. Primary endpoint: Participants achieving hSBA antibody titers at or above 1:8 against meningococcal serogroups A, C, Y, and W.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2020-004341-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004341-36.